80 related articles for article (PubMed ID: 20016304)
1. Spironolactone for all hypertensive patients?
Rosendorff C
J Hypertens; 2010 Jan; 28(1):13-4. PubMed ID: 20016304
[No Abstract] [Full Text] [Related]
2. [Rectal electrical potential difference and plasma aldosterone in hyperaldosteronism and low-, normal- and high-renin hypertension].
Skrabal F; Mauser R
Wien Klin Wochenschr; 1976 Dec; 88(23):777-81. PubMed ID: 1014711
[TBL] [Abstract][Full Text] [Related]
3. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO.
Parthasarathy HK; Alhashmi K; McMahon AD; Struthers AD; McInnes GT; Ford I; Connell JM; MacDonald TM
J Hypertens; 2010 Jan; 28(1):170-7. PubMed ID: 20009770
[TBL] [Abstract][Full Text] [Related]
4. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
5. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
Hood SJ; Taylor KP; Ashby MJ; Brown MJ
Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
Mahmud A; Feely J
Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
[TBL] [Abstract][Full Text] [Related]
7. The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters.
Kaşifoğlu T; Yalçin AU
Anadolu Kardiyol Derg; 2006 Jun; 6(2):143-7. PubMed ID: 16766279
[TBL] [Abstract][Full Text] [Related]
8. Resistant hypertension and aldosterone: an update.
Clark D; Ahmed MI; Calhoun DA
Can J Cardiol; 2012 May; 28(3):318-25. PubMed ID: 22521297
[TBL] [Abstract][Full Text] [Related]
9. [The clinical spectrum of potassium-sparing diuretics].
Greminger P; Suter PM
Praxis (Bern 1994); 1997 Apr; 86(14):556-60. PubMed ID: 9198849
[TBL] [Abstract][Full Text] [Related]
10. Primary aldosteronism: the most frequent form of secondary hypertension?
Shargorodsky M; Zimlichman R
Isr Med Assoc J; 2002 Jan; 4(1):32-3. PubMed ID: 11802308
[No Abstract] [Full Text] [Related]
11. Endothelin-1 and adrenomedullin plasma levels after exposure to fludrocortisone, dexamethasone, and spironolactone.
Vogt S; Winkler E; Hermsen D; Schott M; Schinner S; Scherbaum WA; Willenberg HS
Clin Exp Hypertens; 2012; 34(8):582-7. PubMed ID: 22559244
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.
Gaddam KK; Pratt-Ubunama MN; Calhoun DA
Expert Rev Cardiovasc Ther; 2006 May; 4(3):353-9. PubMed ID: 16716096
[TBL] [Abstract][Full Text] [Related]
13. Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.
Zarnegar R; Lee J; Brunaud L; Lindsay S; Kebebew E; Clark OH; Duh QY
Surgery; 2007 Dec; 142(6):921-9; discussion 921-9. PubMed ID: 18063077
[TBL] [Abstract][Full Text] [Related]
14. Treatment of arterial hypertensive disease with diuretics. V. Spironolactone, an aldosterone antagonist.
Johnston LC; Grieble HG
Arch Intern Med; 1967 Mar; 119(3):225-31. PubMed ID: 6020067
[No Abstract] [Full Text] [Related]
15. [Primary hyperaldosteronism].
Plouin PF; Massien-Simon C
Rev Prat; 1998 Apr; 48(7):749-53. PubMed ID: 11767370
[TBL] [Abstract][Full Text] [Related]
16. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
Mahmud A; Mahgoub M; Hall M; Feely J
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
[TBL] [Abstract][Full Text] [Related]
17. Study of the use of a spironolactone and angiotensin-converting enzyme inhibitor combination: a population-based analysis.
Besançon JF; Lagarce L; Diquet B; Lainé-Cessac P
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):172-9. PubMed ID: 17948926
[TBL] [Abstract][Full Text] [Related]
18. Overlapping spironolactone dosing in primary aldosteronism and resistant essential hypertension.
Handler J
J Clin Hypertens (Greenwich); 2012 Oct; 14(10):732-4. PubMed ID: 23031155
[No Abstract] [Full Text] [Related]
19. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
[TBL] [Abstract][Full Text] [Related]
20. Bilateral adrenal cortical hyperplasia.
Slifer A; Aronoff DM
Tenn Med; 2000 May; 93(5):172-3. PubMed ID: 10821072
[No Abstract] [Full Text] [Related]
[Next] [New Search]
